Efficacy and safety of anlotinib as a third-line treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

Anlotinib is a novel multitarget tyrosine kinase inhibitor, which has been indicated to inhibit both tumor angiogenesis and signal transduction pathways associated with proliferation. The main proposed mechanism of anlotinib inhibiting tumor angiogenesis is that anlotinib inhibits the activation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zha, Bowen, Zhang, Yuxin, Yang, Runzi, Kamili, Muladili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185159/
https://www.ncbi.nlm.nih.gov/pubmed/35720500
http://dx.doi.org/10.3892/ol.2022.13350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185159/
https://www.ncbi.nlm.nih.gov/pubmed/35720500
http://dx.doi.org/10.3892/ol.2022.13350

Ejemplares similares